Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Little bit of goods in today's market sell-off
Another fantastic operator launch! Weâre excited to announce that our Slingo Originals are now live with Coastline Gamingâs Slotbox through our partners Gaming Innovation Group. You can now find many of our games including smash-hits like Slingo Xxxtreme, Slingo Starburst & Deal or No Deal Slingo ??
https://www.gamingintelligence.com/products/casino/137580-pragmatic-play-titles-set-for-slingo-treatment-under-new-partnership/
London-listed Gaming Realms has expanded its licensing portfolio through a new partnership with Pragmatic Play.
The deal announced Monday will enable Gaming Realms to create new Slingo-branded games based on Pragmatic Play IP, including Slingo versions of popular Pragmatic titles Sweet Bonanza and Wolf Gold.
âThis licensing partnership with Pragmatic Play opens up a range of cross-sell benefits to both parties,â said Gaming Realms executive chairman Michael Buckley.
âThe collaboration between two organisations with a key focus on content innovation in the digital space is truly exciting. Pragmatic Play creates engaging and immersive gaming content that fits perfectly with Slingo, weâre hoping this announcement should excite both operators and players.â
Yossi Barzely, chief business development officer at Pragmatic Play, added: âCreating memorable gaming experiences is a priority for us and Gaming Realms has an excellent reputation through its Slingo portfolio.
âWe have an extremely positive feeling about the potential for Pragmatic Play-themed Slingo games and are eager to see this partnership realise its potential.â
Gaming Realms
We are very excited to announce that we have signed a deal with Pragmatic Play to license market-leading brands from their expansive game portfolio, including Sweet Bonanza and Wolf Gold... ?? Watch this space for updates on our upcoming games and partnerships ??
https://www.linkedin.com/mwlite/company/gaming-realms#image-modal
Live casino giant Evolution has entered into an agreement to acquire Megaways developer Big Time Gaming for a total consideration of up to âŹ450m (ÂŁ389.0m/$534.5m), payable in cash and Evolution shares.
https://www.casinobeats.com/2021/04/12/evolution-to-acquire-e450m-big-time-gaming/
CEO is still buying stock.H.C. Wainwright initiates coverage on CEL-SCI to Buy.The American Cancer Society just published a new report and says oral cancer death rates have increased over the past decade.We believe that the trial has a high probability of being successful and that the stock is deeply undervalued.
CEL-SCI Corp.'s (NYSEMKT:CVM) Phase III clinical trial of Multikine is about to end soon. We believe, through the due diligence that we have carried out, there is very little risk the primary endpoint won't be met. However, the risks of investing in a small biotech with limited cash resources and a small pipeline are well-known. The upside of a breakthrough oncology drug is what makes CEL-SCI so attractive.
History
About CEL-SCI and Multikine
CEL-SCI is a small-cap market (~$300 million) clinical-stage cancer bio-pharmaceutical company. Multikine, a ****tail combination of cytokines and chemokines, is a prospective neoadjuvant treatment and an investigational drug candidate in Phase III Event-Driven clinical development for newly diagnosed advanced primary head and neck cancer.
The goal of Multikine is to boost the body's immune system prior to Standard of Care (âSOCâ). The Event-Driven Phase III study is fully enrolled with 928 patients, and the last patient was treated in September 2016.
To prove an overall survival benefit, the study requires CEL-SCI to wait until 298 events (deaths) have occurred among the two main comparator groups. We believe that this 9-year Phase III trial has just ended or will end very soon. Thus, top line results are imminent.
About The Current CRO
The current CRO, Ergomed, has a co-development agreement and has invested $12 million in this trial. The company stands to make 4x its investment if this trial is successful.
A few years into the study, Ergomed's CEO, Miroslav Reljanovic, stated:
At this point in the clinical trial we have decided to increase our investment in the development of Multikine, as we believe that it holds the potential to treat head and neck cancer in a new way. Our potential returns from this agreement will increase in line with our investment.â
It's safe to assume Ergomed's leaders have a sense of the trial's progress, and the increase in the co-development speaks volumes. With Ergomed stock more than doubling recently and significant insider buys, we believe this is a "tell". Read about it here.
https://seekingalpha.com/article/4316612-cel-sci-homestretch